ModifiedPremera BluecrossPolicy MEDICAL POLICY - 2.01.533

Upper Gastrointestinal (UGI) Endoscopy for Adults

Defines medical necessity, documentation, and coding for upper GI endoscopy (EGD) in adults (age 19+) for diagnostic, surveillance, and therapeutic indications for Premera Blue Cross members.

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy for Adults

Policy CodePolicy MEDICAL POLICY - 2.01.533

Change TypeUpdated

Effective DateFeb 1, 2026

Next Review Date

Key ActionDocument indication and prior therapy (including an 8-week daily PPI trial for GERD/dyspepsia) when submitting authorization requests.

SourceLink

POLICY UPDATE CHANGES

This policy has been updated.

19+applies to individuals aged

8 weeksPPI trial required before endoscopy (GERD)

>=3 monthsminimum GERD symptom duration

3-5 yrsBE surveillance interval (no dysplasia)

~7%/yrannual progression risk (HGD)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Upper GI Endoscopy (EGD)

Malignant Indications

Covered when ANY of the following malignant or highly suspicious conditions are present:

Malignant or highly suspicious conditions: Barrett esophagus (metaplastic columnar or glandular epithelium); dysplasia; esophageal cancer; familial adenomatous polyposis (FAP); gastric cancer; head/neck cancer; history of Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC); clinical features highly suspicious for UGI malignancy (e.g., epigastric mass on x‑ray, abnormal barium study); individuals with prior adenomatous or sessile polyps (gastric, duodenal, esophagus); one evaluation for a positive CDH1 mutation; family history of gastric, esophageal, or duodenal cancer in a first‑degree relative; tylosis.

Supported by policy malignant indications section.

Alarm Symptoms

Covered when ANY of the following alarm symptoms are present:

Alarm symptoms: Iron deficiency anemia; bleeding from the rectum or bright/dark blood in stool; dysphagia; recurrent vomiting; unintentional weight loss; epigastric mass on examination.

Alarm symptoms associated with an UGI source per policy and Best Practice Advice.

Follow-up of Known Non-malignant Conditions

Covered when ANY of the following non-malignant but significant conditions are present:

Non-malignant follow-up: Persistent vomiting of unknown cause (including hematemesis); dysphagia; unintentional weight loss ≥3 kg since symptom onset; anorexia of unknown cause; evaluation for suspected portal hypertension/cirrhosis to document or treat esophageal varices; follow-up of eosinophilic esophagitis; follow-up of erosive esophagitis (may need UGI after a 2‑month course of therapy to evaluate for Barrett); therapeutic banding (ligation) or sclerotherapy of esophageal varices with repeat UGI until eradication then surveillance (1–3 months after eradication, then every 6–12 months); treatment of bleeding lesions (e.g., ulcers) requiring endoscopic therapy; history of gastric surgery; persistent symptoms despite stopping NSAIDs; persistent non‑cardiac chest pain; odynophagia.weight loss >= 3 kg; follow-up erosive esophagitis: 2 months

Includes variceal treatment surveillance timing and erosive esophagitis follow-up per policy history.

GERD or Dyspepsia

Covered when ALL of the following are met for evaluation of GERD/dyspepsia:

GERD/dyspepsia criteria: Symptoms present for at least 3 months AND symptoms persist despite 8 weeks of continuous daily proton pump inhibitor (PPI) therapy OR symptoms recur after PPI therapy has been discontinued.symptoms >= 3 months; 8-week continuous daily PPI trial

Policy requires duration of symptoms and prior PPI therapy per ACG/ACP guidance and policy updates.

Other UGI Indications

Covered when ANY of the following specific indications are present:

Other indications: Achalasia; Barrett esophagus surveillance according to dysplasia status (high‑grade dysplasia: repeat UGI every 3 months after initial biopsy for 1 year then annually; low‑grade dysplasia: repeat UGI at 6 months, then at 12 months and annually thereafter; no dysplasia: one repeat within 12 months then every 3 years if unchanged); cirrhosis at initial diagnosis—one screening UGI for esophageal varices then no more frequently than annually for ongoing screening; Crohn disease involving the esophagus/stomach/duodenum; caustic ingestion; removal of foreign body; confirmation of gastric/peptic/esophageal ulcer when conservative management failed or is contraindicated, with follow-up UGI every 2 months until healed; individuals planned for organ transplantation when upper GI pathology may modify management; preoperative evaluation prior to bariatric surgery (unless excluded by contract); newly diagnosed (within 1 year) pernicious anemia; post cardiac ablation; Barrett screening in males ≥50 years with ≥5 years GERD and ≥1 risk factor (elevated BMI, central adiposity, hiatal hernia, night‑time symptoms, tobacco use); assessment of diarrhea when small‑bowel disease or IBD suspected.Barrett screening: male >=50 yrs with >=5 yrs GERD plus >=1 risk factor; ulcer follow-up: every 2 months until healed

Surveillance and screening intervals specified; ASGE indications referenced.

Indications for EGD and Barrett surveillance

Covered when the following indication-based criteria are met

Alarm symptoms: Upper endoscopy is indicated for patients with heartburn plus any alarm symptoms (anemia, bleeding, dysphagia, recurrent vomiting, weight loss).

Based on Best Practice Advice 1 and policy criteria.

Failure of medical therapy: Endoscopy is indicated for patients with typical GERD symptoms that persist despite an appropriate trial of PPI therapy (ACG: 8‑week trial; ACP: 4–8 weeks twice‑daily in specified contexts).8-week PPI trial

See ACG/ACP guidance and policy statements.

High‑risk features for Barrett or cancer: Endoscopy recommended for patients with severe erosive esophagitis after PPI therapy, patients older than 50 with chronic GERD (>5 years) plus additional risk factors, or multiple risk factors for Barrett esophagus to detect Barrett or adenocarcinoma.age > 50 and chronic symptoms > 5 years plus risk factors

Selected medically necessary indications (historical extracts)

Policy includes multiple medically necessary and not medically necessary statements developed and modified over time

GERD/dyspepsia (historical): UGI is medically necessary for evaluation of GERD or dyspepsia symptoms that persist despite 8 weeks of continuous daily PPI therapy OR for evaluation when symptoms return after PPI therapy has been discontinued (history note update 06/01/22).8 weeks PPI trial

Derived from policy history entries.

Bariatric surgery preoperative (historical): Preoperative UGI prior to bariatric surgery was changed from not medically necessary to medically necessary (01/01/23 history entry).

Policy history.

Esophageal varices (historical): Therapeutic banding (ligation) or sclerotherapy of esophageal varices added as medically necessary (09/01/22); surveillance schedule clarified in 01/01/23 entries.

Policy history.

Not medically necessary: Upper gastrointestinal (UGI) endoscopy is not medically necessary for evaluation of chronic, non‑progressive symptoms that are functional in origin, except that a one‑time endoscopic exam may be reasonable in rare cases to exclude organic disease when symptoms are unresponsive to therapy. This includes evaluation of uncomplicated heartburn that responds to conservative medical management, procedures unlikely to alter management, and asymptomatic radiographic findings that are uncomplicated or have responded to therapy.

Sequential or periodic esophagogastroduodenoscopy (EGD) is generally not indicated for surveillance of malignancy in conditions such as gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia, or prior benign gastric operations. Such ongoing surveillance should not be performed routinely unless specific clinical indications or other guidance support it.

Surveillance endoscopy for healed benign disease (for example, healed gastric or duodenal ulcers) is considered not medically necessary. The policy explicitly states that follow‑up solely to confirm healing or for routine surveillance of previously healed benign lesions is not an appropriate indication for repeat UGI when it will not change clinical management.

Not medically necessary: UGI endoscopy is considered not medically necessary whenever the documented clinical criteria for a medically necessary indication are not met. Examples include evaluation of uncomplicated heartburn responsive to conservative therapy, routine screening in the absence of clinical indications, and surveillance exams that are unlikely to affect treatment or outcomes.

EGD is generally not indicated for symptoms judged to be functional in origin when no other indications are present. Professional guidance cited in the policy supports limiting endoscopy for functional complaints except for rare one‑time exams to exclude organic disease or when symptoms fail to respond to therapy; asymptomatic/incidental findings (e.g., uncomplicated sliding hiatal hernia) that will not alter management are also not valid indications for EGD.

UGI performed for surveillance of individuals with gastric intestinal metaplasia is considered not medically necessary as of the 02/01/23 policy entry. The history and policy updates state that routine surveillance for gastric intestinal metaplasia is not supported and should not be performed absent other qualifying clinical indications.

Coding and Procedure Codes

Covered CPT CodesCPTCovered

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures).
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple.
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).

Historical CPT coding notesCPT

43233-43270 (range mentioned historically)

CPT codes referenced historically; specific codes were added/removed in multiple history entries (e.g., 43233, 43253, 43254, 43266, 43270 added in 2014; various codes removed in later edits).

PPI trial — prior medical therapy requirement

Required duration8 weeks of continuous daily proton pump inhibitor (PPI) therapy

ContextRequired prior to consideration of endoscopy for GERD/dyspepsia when symptoms persist despite therapy

Alternate dosing guidanceACP notes 4–8 weeks twice‑daily PPI in some contexts; ACG recommends 8‑week once‑daily empiric trial for classic symptoms

Provider Actions, Authorization, and Documentation

Prior Authorization

Submit with listed CPT codes

Submit prior authorization requests using the listed EGD procedure codes: CPT 43235, 43238, 43239, and 43242.

CPT 43235
CPT 43238
CPT 43239
CPT 43242

Prior Authorization

Prior authorization: medical necessity required

Endoscopic procedures require documentation that the service is reasonable and necessary for the individual patient; prior authorization may be required per payer rules.

Note

Verify prior authorization and benefits

Background and Rationale

Upper GI endoscopy (EGD) inspects the esophagus, stomach, and duodenum using a flexible endoscope and serves both diagnostic and therapeutic purposes, including biopsy, treatment of bleeding lesions, polypectomy, foreign body removal, dilation of strictures, placement of feeding tubes, and endoscopic ultrasound‑guided fine needle aspiration/biopsy of adjacent organs or structures. Conservative medical management is recommended first when no clear cancer or other qualifying indication exists.

Definitions and Clinical Concepts

Achalasia

DefinitionAn esophageal motility disorder involving the smooth muscle of the esophagus and the lower esophageal sphincter (LES).

Clinical relevanceMay warrant endoscopic evaluation as a specific indication for UGI endoscopy.

Related termsMay be evaluated in the context of dysphagia or persistent vomiting.

Barrett esophagus

DefinitionReplacement of normal squamous epithelium by metaplastic columnar or glandular epithelium in the esophagus; predisposes to esophageal adenocarcinoma.

Surveillance implicationPatients with Barrett esophagus are candidates for endoscopic surveillance per dysplasia status (see surveillance categories).

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy for Adults

Policy CodePolicy MEDICAL POLICY - 2.01.533

Change TypeUpdated

Effective DateFeb 1, 2026

Next Review Date

Key ActionDocument indication and prior therapy (including an 8-week daily PPI trial for GERD/dyspepsia) when submitting authorization requests.

SourceLink

On This Page

Per Best Practice Advice 3 and ACG statements.

Barrett esophagus surveillance: Surveillance intervals per ACG/ACP: no dysplasia — endoscopy every 3–5 years; low‑grade dysplasia — endoscopic therapy or surveillance every 12 months (policy adds option: repeat at 6 months then 12 months then annually); high‑grade dysplasia — endoscopic therapy.no dysplasia: 3–5 years; LGD: 12 months (or 6 months then 12 mo then annually per policy update); HGD: endoscopic therapy

ACG recommendations and policy history (03/01/24) clarify LGD schedule; some groups disagree about routine surveillance for no dysplasia.

Other ASGE indications: EGD is indicated for persistent upper abdominal symptoms despite therapy, dysphagia/odynophagia, persistent vomiting, GI bleeding, need for tissue sampling, suspected varices, and preoperative evaluation where upper GI pathology may alter management.

Based on ASGE Standards of Practice.

Follow-up of erosive esophagitis (historical): Clarified two‑month course of therapy under criteria for follow-up of known erosive esophagitis (06/01/21).2 months

Policy history.

Surveillance Barrett's esophagus (historical): Update (03/01/24) added BE surveillance schedule for low‑grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter.6 months then 12 months then annually

Policy history.

Small bowel disease/IBD evaluation (historical): UGI is medically necessary to assess diarrhea in individuals suspected of having small‑bowel disease (e.g., celiac disease) or IBD (01/01/23).

Policy history.

EUS‑guided FNA (historical): UGI is medically necessary when performed for endoscopic ultrasound‑guided fine needle aspiration/biopsy(s) of adjacent organs or structures (10/01/23).

Policy history.

This policy is a guide for medical necessity determinations; verify member benefits and whether prior authorization is required with the payer or member services before scheduling.

Step Therapy

Medical therapy prior to endoscopy

For GERD/dyspepsia indications, document a trial of at least 8 weeks of continuous daily proton pump inhibitor (PPI) therapy prior to consideration of endoscopy; H2 receptor antagonists may be used only if PPIs are not tolerated or contraindicated.

Step Therapy

Empiric PPI trial before endoscopy

An empiric PPI trial is expected prior to diagnostic endoscopy for classic GERD symptoms — typically an 8‑week once‑daily PPI trial (ACG recommendation); ACP guidance allows 4–8 weeks twice‑daily in specified contexts.

Step Therapy

PPI trial for GERD/dyspepsia

For GERD/dyspepsia indications the policy requires symptoms to persist despite an 8‑week trial of continuous daily PPI therapy or to recur after PPI discontinuation before EGD is considered medically necessary.

Documentation Required

Required documentation

Clinical notes must document the indication for EGD in individuals aged 19 years or older, including malignant indications, alarm symptoms, high‑risk non‑malignant conditions, duration of GERD/dyspepsia, and prior PPI therapy details.

Document age (≥19 years)
Document malignant or alarm symptoms when present
Document GERD duration (≥3 months) and prior PPI trial (8 weeks continuous daily)
Document other specific GI indications as applicable

Documentation Required

Indication documentation

Document presence of alarm symptoms (e.g., anemia, bleeding, dysphagia, recurrent vomiting, weight loss) and failure of an appropriate trial of therapy (e.g., 8‑week once‑daily PPI per ACG or 4–8 weeks twice‑daily per ACP) to justify EGD when no alarm features exist.

List any alarm symptoms present
Record prior PPI regimen and duration
If PPI not tolerated, document contraindication and alternative therapy

Documentation Required

Clinical documentation

Provide clinical documentation per policy to support medical necessity determinations; policy history notes documentation requirements were added and providers should supply relevant clinical notes and prior treatment records.

Denial Risk

Denial triggers for UGI endoscopy

UGI endoscopy is considered not medically necessary when the policy criteria are not met — e.g., uncomplicated heartburn responsive to conservative care, routine screening without indication, surveillance of healed benign disease, or surveillance of gastric intestinal metaplasia.

Denial Risk

Medical necessity required

Endoscopic procedures are covered only when reasonable and necessary for the individual patient; lack of documentation of medical necessity may lead to claim denial.

Billing Rule

Benefit verification required

Confirm coverage limits and conditions in the member's benefit plan and contact member services to verify whether the service is covered and whether prior authorization or contract exclusions (e.g., bariatric exclusions) apply.

Associated conditionOften related to chronic gastroesophageal reflux disease (GERD).

Gastroesophageal reflux disease (GERD)

DefinitionA chronic digestive disorder in which stomach contents reflux into the esophagus causing heartburn, regurgitation, and sometimes noncardiac chest pain.

DiagnosisBased on symptoms, endoscopy, ambulatory reflux monitoring, and response to antisecretory therapy (PPI).

Initial managementAn empiric 8‑week once‑daily PPI trial is recommended for classic GERD symptoms before endoscopy.

Barrett esophagus surveillance categories

No dysplasiaEstimated progression to cancer ~0.2–0.5% per year; ACG recommends surveillance every 3–5 years.

Low‑grade dysplasiaEstimated progression ~0.7% per year; ACG recommends endoscopic therapy or surveillance every 12 months.

High‑grade dysplasiaEstimated progression ~7% per year; ACG recommends endoscopic therapy.

GERD diagnostic approach

Diagnostic elementsDiagnosis of GERD uses symptom assessment, endoscopy, reflux monitoring, and response to antisecretory therapy.

Empiric PPI recommendationFor classic GERD symptoms without alarm features, an empiric 8‑week once‑daily PPI trial before endoscopy is recommended (ACG).

Endoscopy indicationsPerform diagnostic endoscopy if symptoms do not respond to an 8‑week PPI trial or if symptoms recur after PPI discontinuation; endoscopy is first test with alarm symptoms or dysphagia.

UGI (Upper Gastrointestinal Endoscopy / EGD)

Procedure definitionEndoscopic examination of the esophagus, stomach, and duodenum used for diagnostic and therapeutic purposes including biopsy and treatment of bleeding.

SynonymEsophagogastroduodenoscopy (EGD) is used interchangeably with UGI endoscopy.

Clinical usesUsed for surveillance (e.g., Barrett esophagus), tissue sampling, variceal assessment/therapy, foreign body removal, and preoperative evaluation.